The "how" of antibody discovery is undergoing a significant transformation in 2025. A deep Antibody Drug Discovery Market Analysis shows that the Phage Display segment is projected to account for a 50.3% market share by 2035. This method is favored for its robustness in producing high-affinity biologics and its ability to screen massive libraries without the ethical constraints of animal immunization. In 2025, advancements in phage display are being coupled with automation to process millions of candidates simultaneously.

Simultaneously, Single-B-Cell Screening is emerging as a high-growth technique, particularly for the discovery of "fully human" antibodies. By isolating and sequencing individual B-cells from vaccinated or recovered human donors, researchers can recover functional antibodies that have already been "safety-tested" by the human immune system. In October 2024, Rapid Novor demonstrated a breakthrough in REpAb sequencing that successfully recovered functional antibodies from human serum, proving the viability of this approach for rapid response to infectious diseases.

Finally, Hybridoma Technology—the traditional workhorse of the industry—captured 38.1% of the share in 2024. While it remains a standard for producing high-quality murine antibodies, it is gradually being replaced by transgenic animal platforms and AI-enabled in silico design. As we move toward 2030, the market is expected to settle into a "Hybrid Workflow," where AI designs the initial sequences, and automated phage display or single-cell systems validate their biological function in a high-throughput environment.

FAQ: Why is Phage Display so popular? Ans: It allows for the screening of billions of antibody variants quickly and can be done entirely in a lab setting, avoiding the use of animals while producing highly specific drug candidates.